

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ON-MARKET PURCHASE OF SHARES PURSUANT TO THE 2026 SHARE AWARD SCHEME

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”) dated 25 March 2026 in relation to the adoption of the 2026 CSPC Restricted Share Award Scheme (the “**2026 Share Award Scheme**”) of the Company (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

On 25 June 2026, the Trustee purchased a total of 5,950,000 Shares on-market to be held on trust for the benefit of the Selected Participants pursuant to the terms and conditions of the 2026 Share Award Scheme. Details of the Shares purchased and held on trust by the Trustee are as follows:

Total number of Shares purchased:	5,950,000 Shares
The number of Shares purchased as a percentage of Shares in issue as at the date of this announcement:	Approximately 0.05%
Average price per Share:	Approximately HK\$6.655
Total consideration for the Shares purchased (excluding the transaction costs):	Approximately HK\$39,597,000

Information on the Shares held by the Trustee as at the date of this announcement is as follows:

Number of Shares held by the Trustee:	41,778,000 Shares
The number of Shares held by the Trustee as a percentage of the total number of Shares in issue:	Approximately 0.36%

In addition, as at the date of this announcement, BOCI-Prudential Trustee Limited, the trustee of the 2018 Share Award Scheme, holds 117,000,000 shares on trust pursuant to the terms and conditions of such scheme.

The Board will from time to time review and determine at its absolute discretion the number of Shares to be awarded to the selected participants under the 2018 Share Award Scheme and the 2026 Share Award Scheme as it may deem appropriate, and the number of Shares to be further purchased on-market under the 2026 Share Award Scheme.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 25 June 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.